AAAAAA

   
Results: 1-25 | 26-50
Results: 1-25/50
PHASE I IIA SAFETY, IMMUNOGENICITY, AND EFFICACY TRIAL OF NYVAC-PF7, A POX-VECTORED, MULTIANTIGEN, MULTISTAGE VACCINE CANDIDATE FOR PLASMODIUM-FALCIPARUM MALARIA/
Authors: OCKENHOUSE CF SUN PF LANAR DE WELLDE BT HALL BT KESTER K STOUTE JA MAGILL A KRZYCH U FARLEY L WIRTZ RA SADOFF JC KASLOW DC KUMAR S CHURCH LWP CRUTCHER JM WIZEL B HOFFMAN S LALVANI A HILL AVS TINE JA GUITO KP DETAISNE C ANDERS R HORII T PAOLETTI E BALLOU WR
Citation: Cf. Ockenhouse et al., PHASE I IIA SAFETY, IMMUNOGENICITY, AND EFFICACY TRIAL OF NYVAC-PF7, A POX-VECTORED, MULTIANTIGEN, MULTISTAGE VACCINE CANDIDATE FOR PLASMODIUM-FALCIPARUM MALARIA/, The Journal of infectious diseases, 177(6), 1998, pp. 1664-1673
SAFETY AND IMMUNOGENICITY OF A BIVALENT HAEMOPHILUS-INFLUENZAE TYPE-BHEPATITIS-B VACCINE IN HEALTHY INFANTS
Authors: WEST DJ HESLEY TM JONAS LC FEELEY LK BIRD SR BURKE P SADOFF JC BROMBERG K CHARTRAND S JOHNSON D KEYSERLING H PETERSEN K RABALAIS G REISINGER K ROTHSTEIN E SETO D SULLIVAN B WATSON B
Citation: Dj. West et al., SAFETY AND IMMUNOGENICITY OF A BIVALENT HAEMOPHILUS-INFLUENZAE TYPE-BHEPATITIS-B VACCINE IN HEALTHY INFANTS, The Pediatric infectious disease journal, 16(6), 1997, pp. 593-599
ATTENUATED BACTERIA AS A DNA DELIVERY VEHICLE FOR DNA-MEDIATED IMMUNIZATION
Authors: SIZEMORE DR BRANSTROM AA SADOFF JC
Citation: Dr. Sizemore et al., ATTENUATED BACTERIA AS A DNA DELIVERY VEHICLE FOR DNA-MEDIATED IMMUNIZATION, Vaccine, 15(8), 1997, pp. 804-807
DOUBLE-BLIND VACCINE-CONTROLLED RANDOMIZED EFFICACY TRIAL OF AN INVESTIGATIONAL SHIGELLA-SONNEI CONJUGATE VACCINE IN YOUNG-ADULTS
Authors: COHEN D ASHKENAZI S GREEN MS GDALEVICH M ROBIN G SLEPON R YAVZORI M ORR N BLOCK C ASHKENAZI I SHEMER J TAYLOR DN HALE TL SADOFF JC PAVLIAKOVA D SCHNEERSON R ROBBINS JB
Citation: D. Cohen et al., DOUBLE-BLIND VACCINE-CONTROLLED RANDOMIZED EFFICACY TRIAL OF AN INVESTIGATIONAL SHIGELLA-SONNEI CONJUGATE VACCINE IN YOUNG-ADULTS, Lancet, 349(9046), 1997, pp. 155-159
CONFIRMATORY INTERLEUKIN-1 RECEPTOR ANTAGONIST TRIAL IN SEVERE SEPSIS- A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL
Authors: OPAL SM FISHER CJ DHAINAUT JFA VINCENT JL BRASE R LOWRY SF SADOFF JC SLOTMAN GJ LEVY H BALK RA SHELLY MP PRIBBLE JP LABRECQUE JF LOOKABAUGH J DONOVAN H DUBIN H BAUGHMAN R NORMAN J DEMARIA E MATZEL K ABRAHAM E SENEFF M BARBER A BRAYMAN K CERRA F CHALFIN D CHAZEN G CHRISTOU N COONEY R CORBIN R DREW R EMMANUEL G PINES B ERON L FLETCHER R FOULKE G GALLAGHER T GERVICH D GROSSMAN J HALPERN N HANNA C JOHNSON S KUBAK B LODATO R LOVETT M MARSHALL J METZLER M NELSON L FREELAND M OROPELLO J PAZ H RACKOW E RIKER R RISSING P SCHEIN R SCHELD M SCHUSTER D SIBBALD W SILVERMAN H SOMERMEYER M STRANGE C SUMMER W TOPIEL M WHITE J ALESTIG K ANDERSEN PK ANDERSSON J BENNETT D BERG S BLEICHNER G BRUNET F CARLET J DEJONG MJ DREXLER H GARRARD C HESLET L KLOSS T PAUL W REINHART K RENAUD B RITZ R ROMME JH SCHMITZ JE STOCKENHUBER F SUTER P TENAILLON A VAGT A VANDERMEER WM VANDEVENTER S VANLEEUWEN PAM VERHOEF J WEBSTER N WINTER RJ WOLFF M STILES DM DEVOS A CROFT C FAZIO J THOMPSON R WIEDEMANN H ELLISON RT CHINCHILLI VM YARBOROUGH M
Citation: Sm. Opal et al., CONFIRMATORY INTERLEUKIN-1 RECEPTOR ANTAGONIST TRIAL IN SEVERE SEPSIS- A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, Critical care medicine, 25(7), 1997, pp. 1115-1124
INFLUENCE OF ALTERATIONS IN FORGOING LIFE-SUSTAINING TREATMENT PRACTICES ON A CLINICAL SEPSIS TRIAL (VOL 25, PG 386, 1997)
Authors: SPRUNG CL EIDELMAN LA PIZOV R FISHER CJ ZIEGLER EJ SADOFF JC STRAUBE RC MCCLOSKEY RV
Citation: Cl. Sprung et al., INFLUENCE OF ALTERATIONS IN FORGOING LIFE-SUSTAINING TREATMENT PRACTICES ON A CLINICAL SEPSIS TRIAL (VOL 25, PG 386, 1997), Critical care medicine, 25(6), 1997, pp. 1092-1092
INFLUENCE OF ALTERATIONS IN FORGOING LIFE-SUSTAINING TREATMENT PRACTICES ON A CLINICAL SEPSIS TRIAL
Authors: SPRUNG CL EIDELMAN LA PIZOV R FISHER CJ ZIEGLER EJ SADOFF JC STRAUBE RC MCCLOSKEY RV
Citation: Cl. Sprung et al., INFLUENCE OF ALTERATIONS IN FORGOING LIFE-SUSTAINING TREATMENT PRACTICES ON A CLINICAL SEPSIS TRIAL, Critical care medicine, 25(3), 1997, pp. 383-387
PHASE-I TRIAL OF THE SPF66 MALARIA VACCINE IN A MALARIA-EXPERIENCED POPULATION IN SOUTHEAST-ASIA
Authors: NOSTEN F LUXEMBURGER C KYLE DE GORDON DM BALLOU WR SADOFF JC BROCKMAN A PERMPANICH B CHONGSUPHAJAISIDDHI T HEPPNER DG
Citation: F. Nosten et al., PHASE-I TRIAL OF THE SPF66 MALARIA VACCINE IN A MALARIA-EXPERIENCED POPULATION IN SOUTHEAST-ASIA, The American journal of tropical medicine and hygiene, 56(5), 1997, pp. 526-532
DNA VACCINES
Authors: ULMER JB SADOFF JC LIU MA
Citation: Jb. Ulmer et al., DNA VACCINES, Current opinion in immunology, 8(4), 1996, pp. 531-536
PLASMODIUM-FALCIPARUM CIRCUMSPOROZOITE VACCINE IMMUNOGENICITY AND EFFICACY TRIAL WITH NATURAL CHALLENGE QUANTITATION IN AN AREA OF ENDEMIC HUMAN MALARIA OF KENYA
Authors: SHERWOOD JA COPELAND RS TAYLOR KA ABOK K OLOO AJ WERE JBO STRICKLAND GT GORDON DM BALLOU WR BALES JD WIRTZ RA WITTES J GROSS M QUE JU CRYZ SJ OSTER CN ROBERTS CR SADOFF JC
Citation: Ja. Sherwood et al., PLASMODIUM-FALCIPARUM CIRCUMSPOROZOITE VACCINE IMMUNOGENICITY AND EFFICACY TRIAL WITH NATURAL CHALLENGE QUANTITATION IN AN AREA OF ENDEMIC HUMAN MALARIA OF KENYA, Vaccine, 14(8), 1996, pp. 817-827
RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF SPF66 MALARIA VACCINE IN CHILDREN IN NORTHWESTERN THAILAND
Authors: NOSTEN F LUXEMBURGER C KYLE DE BALLOU WR WITTES J WAH E CHONGSUPHAJAISIDDHI T GORDON DM WHITE NJ SADOFF JC HEPPNER DG BATHE K BLOOD J BROCKMAN A COBLEY UT HACKING D HOGG D U KH MAELANKIRI L CHUANAK N PERMPANICH B PRICE R RAIMOND D SCHABENBERGER O SINGHARAJ P SINGHASIVANON P SLIGHT T TULAYON S TWAY KL YNINT T VINCENTIDELMAS M DEVRIES A WEBSTER HK
Citation: F. Nosten et al., RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF SPF66 MALARIA VACCINE IN CHILDREN IN NORTHWESTERN THAILAND, Lancet, 348(9029), 1996, pp. 701-707
USE OF PREDICTED RISK OF MORTALITY TO EVALUATE THE EFFICACY OF ANTICYTOKINE THERAPY IN SEPSIS
Authors: KNAUS WA HARRELL FE LABRECQUE JF WAGNER DP PRIBBLE JP DRAPER EA FISHER CJ SOLL L ASTIZ M RACKOW EC CARPATI C BALK RA FRIEDMAN B MURE AJ SHAPIRO E MELHOM L SHAPIRO MJ TAYLOR R KEEGAN M OBRIEN J GREENMAN RL SCHEIN R PENA M WASSERLOUF M IBERTI TJ OROPELLO J BENJAMIN E DELGUIDICE R EMMANUEL G LIE T ANDERSON L MARSHALL J DEMAJO W ROTSTEIN O FOSTER D ABRAHAM E MIDDLETON H PERRY C LEVY H FRY DE SIMPSON SQ CROWELL RE NEIDHART M STEVENS D COFFMAN T NARASIMHAN N MERRICK DK BERQUIST W MATZEL K HUEBLER M FOULKE G ALBERTSON T WALBY W ALLEN R BAUGHMAN R HASSELGREN PO FINK MP FAVORITO F THOMAS BT CORBIN R SHELLHORSE GY FRAZIER A WHITE S GARRARD C ACOURT C GERVICH D BRASE R BAGDAHN A COONEY R SMITH JS VINCENT JL FRIEDMAN G BERLOT G FLETCHER JR WILLIAMS MD WRIGHT TF JOHNSON S FEILD C WOLF K MACINTYRE N DUBIN H DURKIN M STAUBACH KH FEIN AM SCHULMAN DB NIEDERMAN MS CHALFIN DB VANLEEUVEN PAM BANDER J IMM A BERNARD G NELSON L STROUD M SAFCSAK K CERRA F RINDAL J MANN H HALPERN N ALICEA M SIBBALD WJ MARTIN CM RUTLEDGE FS PETTI K RUSSELL J KRUGER R DRUMMOND A FISHER CS LANGE P SELFERT T DUROCHER A TENAILLON A BOITEAU R LHERM T LOWRY S COYLE SM BARIE PS DEMARIA E REINES HD SNYDMAN D SCHWAITZBERG S NASRAWAY S GRINDLINGER J SUMMER W DEBOISBLANC B WAHL M ALESTIG K GROSSMAN J MAKI D PAZ HL WEINER M BIHARI D BLEICHNER G DAHN M HALL J WENZEL RP GROSSERODE M COSTIGAN M MILESKI W WEIGELT J YESTON N IRIZARRY C ROSS J ROBBINS J SHELLY MP NIGHTINGALE P OWEN K SANDSTEDT S BERG S SIMON G SENEFF M CONRY K ZIMMERMAN JL DELLINGER RP JOHNSTON R ALLEE P GRANDE PO MYHRE E DHAINAUT JF HAMY I MIRA JP HARMON J WHITE J MCKIE L SILVERMAN H TUMA P BENNETT D LAURELL MH JACOBS S ASH S OPAL SM SLOTMAN GJ IBERTI TJ SADOFF JC STILES DM THOMPSON B PRIOR MJ KNATTERUD G TERRIN M KUFERA J WILKENS P RA K MONROE L SPRUNG C HAMILTON CM MATTHAY R MCCABE W TONASCIA J WIEDMAN H WITTES J THOMPSON BW LABRECQUE JF CATALANO MA CAMPION GV CROFT CR LUSTICK R LOOKABAUGH J GORDON GS NOE L BLOEDOW D SMITH CG BRANNON D KUSH R NG D MOORE E BAZEMORE K GALVAN M WAGNER D HARRELL F STABLEIN D
Citation: Wa. Knaus et al., USE OF PREDICTED RISK OF MORTALITY TO EVALUATE THE EFFICACY OF ANTICYTOKINE THERAPY IN SEPSIS, Critical care medicine, 24(1), 1996, pp. 46-56
TREATMENT OF SEPTIC SHOCK WITH THE TUMOR-NECROSIS-FACTOR RECEPTOR-FC FUSION PROTEIN
Authors: FISHER CJ AGOSTI JM OPAL SM LOWRY SF BALK RA SADOFF JC ABRAHAM E SCHEIN RMH BENJAMIN E
Citation: Cj. Fisher et al., TREATMENT OF SEPTIC SHOCK WITH THE TUMOR-NECROSIS-FACTOR RECEPTOR-FC FUSION PROTEIN, The New England journal of medicine, 334(26), 1996, pp. 1697-1702
DEVELOPMENT OF A PURIFIED, INACTIVATED, DENGUE-2 VIRUS-VACCINE PROTOTYPE IN VERO CELLS - IMMUNOGENICITY AND PROTECTION IN MICE AND RHESUS-MONKEYS
Authors: PUTNAK R BARVIR DA BURROUS JM DUBOIS DR DANDREA VM HOKE CH SADOFF JC ECKELS KH
Citation: R. Putnak et al., DEVELOPMENT OF A PURIFIED, INACTIVATED, DENGUE-2 VIRUS-VACCINE PROTOTYPE IN VERO CELLS - IMMUNOGENICITY AND PROTECTION IN MICE AND RHESUS-MONKEYS, The Journal of infectious diseases, 174(6), 1996, pp. 1176-1184
SAFETY, IMMUNOGENICITY, AND EFFICACY OF PLASMODIUM-FALCIPARUM REPEATLESS CIRCUMSPOROZOITE PROTEIN VACCINE ENCAPSULATED IN LIPOSOMES
Authors: HEPPNER DG GORDON DM GROSS M WELLDE B LEITNER W KRZYCH U SCHNEIDER I WIRTZ RA RICHARDS RL TROFA A HALL T SADOFF JC BOERGER P ALVING CR SYLVESTER DR PORTER TG BALLOU WR
Citation: Dg. Heppner et al., SAFETY, IMMUNOGENICITY, AND EFFICACY OF PLASMODIUM-FALCIPARUM REPEATLESS CIRCUMSPOROZOITE PROTEIN VACCINE ENCAPSULATED IN LIPOSOMES, The Journal of infectious diseases, 174(2), 1996, pp. 361-366
SIALYLATION LESSENS THE INFECTIVITY OF NEISSERIA-GONORRHOEAE MS11MKC
Authors: SCHNEIDER H SCHMIDT KA SKILLMAN DR VANDEVERG L WARREN RL WYLIE HJ SADOFF JC DEAL CD CROSS AS
Citation: H. Schneider et al., SIALYLATION LESSENS THE INFECTIVITY OF NEISSERIA-GONORRHOEAE MS11MKC, The Journal of infectious diseases, 173(6), 1996, pp. 1422-1427
A NONCOVALENT COMPLEX VACCINE PREPARED WITH DETOXIFIED ESCHERICHIA-COLI J5 (RC CHEMOTYPE) LIPOPOLYSACCHARIDE AND NEISSERIA-MENINGITIDIS GROUP-B OUTER-MEMBRANE PROTEIN PRODUCES PROTECTIVE ANTIBODIES AGAINST GRAM-NEGATIVE BACTEREMIA
Authors: BHATTACHARJEE AK OPAL SM TAYLOR R NASO R SEMENUK M ZOLLINGER WD MORAN EE YOUNG L HAMMACK C SADOFF JC CROSS AS
Citation: Ak. Bhattacharjee et al., A NONCOVALENT COMPLEX VACCINE PREPARED WITH DETOXIFIED ESCHERICHIA-COLI J5 (RC CHEMOTYPE) LIPOPOLYSACCHARIDE AND NEISSERIA-MENINGITIDIS GROUP-B OUTER-MEMBRANE PROTEIN PRODUCES PROTECTIVE ANTIBODIES AGAINST GRAM-NEGATIVE BACTEREMIA, The Journal of infectious diseases, 173(5), 1996, pp. 1157-1163
NYVAC-PF7 - A POXVIRUS-VECTORED, MULTIANTIGEN, MULTISTAGE VACCINE CANDIDATE FOR PLASMODIUM-FALCIPARUM MALARIA
Authors: TINE JA LANAR DE SMITH DM WELLDE BT SCHULTHEISS P WARE LA KAUFFMAN EB WIRTZ RA DETAISNE C HUI GSH CHANG SP CHURCH P HOLLINGDALE MR KASLOW DC HOFFMAN S GUITO KP BALLOU WR SADOFF JC PAOLETTI E
Citation: Ja. Tine et al., NYVAC-PF7 - A POXVIRUS-VECTORED, MULTIANTIGEN, MULTISTAGE VACCINE CANDIDATE FOR PLASMODIUM-FALCIPARUM MALARIA, Infection and immunity, 64(9), 1996, pp. 3833-3844
ATTENUATED VACCINIA VIRUS-CIRCUMSPOROZOITE PROTEIN RECOMBINANTS CONFER PROTECTION AGAINST RODENT MALARIA
Authors: LANAR DE TINE JA DETAISNE C SEGUIN MC COX WI WINSLOW JP WARE LA KAUFFMAN EB GORDON D BALLOU WR PAOLETTI E SADOFF JC
Citation: De. Lanar et al., ATTENUATED VACCINIA VIRUS-CIRCUMSPOROZOITE PROTEIN RECOMBINANTS CONFER PROTECTION AGAINST RODENT MALARIA, Infection and immunity, 64(5), 1996, pp. 1666-1671
SAFETY AND IMMUNOGENICITY OF INVESTIGATIONAL SHIGELLA CONJUGATE VACCINES IN ISRAELI VOLUNTEERS
Authors: COHEN D ASHKENAZI S GREEN M LERMAN Y SLEPON R ROBIN G ORR N TAYLOR DN SADOFF JC CHU CY SHILOACH J SCHNEERSON R ROBBINS JB
Citation: D. Cohen et al., SAFETY AND IMMUNOGENICITY OF INVESTIGATIONAL SHIGELLA CONJUGATE VACCINES IN ISRAELI VOLUNTEERS, Infection and immunity, 64(10), 1996, pp. 4074-4077
PHASE-I SAFETY AND IMMUNOGENICITY TESTING OF CLINICAL LOTS OF THE SYNTHETIC PLASMODIUM-FALCIPARUM VACCINE SPF66 PRODUCED UNDER GOOD MANUFACTURING PROCEDURE CONDITIONS IN THE UNITED-STATES
Authors: GORDON DM DUFFY PE HEPPNER DG LYON JA WILLIAMS JS SCHEUMANN D FARLEY L STACEY D HAYNES JD SADOFF JC BALLOU WR
Citation: Dm. Gordon et al., PHASE-I SAFETY AND IMMUNOGENICITY TESTING OF CLINICAL LOTS OF THE SYNTHETIC PLASMODIUM-FALCIPARUM VACCINE SPF66 PRODUCED UNDER GOOD MANUFACTURING PROCEDURE CONDITIONS IN THE UNITED-STATES, The American journal of tropical medicine and hygiene, 55(1), 1996, pp. 63-68
USE OF AZITHROMYCIN FOR THE TREATMENT OF CAMPYLOBACTER ENTERITIS IN TRAVELERS TO THAILAND, AN AREA WHERE CIPROFLOXACIN RESISTANCE IS PREVALENT
Authors: KUSCHNER RA TROFA AF THOMAS RJ HOGE CW PITARANGSI C AMATO S OLAFSON RP ECHEVERRIA P SADOFF JC TAYLOR DN
Citation: Ra. Kuschner et al., USE OF AZITHROMYCIN FOR THE TREATMENT OF CAMPYLOBACTER ENTERITIS IN TRAVELERS TO THAILAND, AN AREA WHERE CIPROFLOXACIN RESISTANCE IS PREVALENT, Clinical infectious diseases, 21(3), 1995, pp. 536-541
EVALUATION OF THE SAFETY, IMMUNOGENICITY, AND EFFICACY IN HEALTHY-ADULTS OF 4 DOSES OF LIVE ORAL HYBRID ESCHERICHIA-COLI SHIGELLA-FLEXNERI 2A VACCINE STRAIN ECSF2A-2
Authors: KOTLOFF KL LOSONSKY GA NATARO JP WASSERMAN SS HALE TL TAYLOR DN NEWLAND JW SADOFF JC FORMAL SB LEVINE MM
Citation: Kl. Kotloff et al., EVALUATION OF THE SAFETY, IMMUNOGENICITY, AND EFFICACY IN HEALTHY-ADULTS OF 4 DOSES OF LIVE ORAL HYBRID ESCHERICHIA-COLI SHIGELLA-FLEXNERI 2A VACCINE STRAIN ECSF2A-2, Vaccine, 13(5), 1995, pp. 495-502
A MODIFIED SHIGELLA VOLUNTEER CHALLENGE MODEL IN WHICH THE INOCULUM IS ADMINISTERED WITH BICARBONATE BUFFER - CLINICAL-EXPERIENCE AND IMPLICATIONS FOR SHIGELLA INFECTIVITY
Authors: KOTLOFF KL NATARO JP LOSONSKY GA WASSERMAN SS HALE TL TAYLOR DN SADOFF JC LEVINE MM
Citation: Kl. Kotloff et al., A MODIFIED SHIGELLA VOLUNTEER CHALLENGE MODEL IN WHICH THE INOCULUM IS ADMINISTERED WITH BICARBONATE BUFFER - CLINICAL-EXPERIENCE AND IMPLICATIONS FOR SHIGELLA INFECTIVITY, Vaccine, 13(16), 1995, pp. 1488-1494
SAFETY, IMMUNOGENICITY, AND EFFICACY OF LIVE ATTENUATED VIBRIO-CHOLERAE O139 VACCINE PROTOTYPE
Authors: COSTER TS KILLEEN KP WALDOR MK BEATTIE DT SPRIGGS DR KENNER JR TROFA A SADOFF JC MEKALANOS JJ TAYLOR DN
Citation: Ts. Coster et al., SAFETY, IMMUNOGENICITY, AND EFFICACY OF LIVE ATTENUATED VIBRIO-CHOLERAE O139 VACCINE PROTOTYPE, Lancet, 345(8955), 1995, pp. 949-952
Risultati: 1-25 | 26-50